{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:11:55Z","timestamp":1793056315909,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA151652"],"award-info":[{"award-number":["CA151652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007421","name":"Li Ka Shing Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["07180556"],"award-info":[{"award-number":["07180556"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["16170451"],"award-info":[{"award-number":["16170451"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["C4045-18W"],"award-info":[{"award-number":["C4045-18W"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["14120621"],"award-info":[{"award-number":["14120621"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ymthe.2022.09.012","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T01:38:03Z","timestamp":1663810683000},"page":"119-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Xiaoyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung Hang Jonathan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Jao-yiu","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leaf","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2345-6951","authenticated-orcid":false,"given":"Alfred Sze-lok","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.09.012_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2022.09.012_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.09.012_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2022.09.012_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2022.09.012_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2009.08.008","article-title":"Immune tolerance: what is unique about the liver","volume":"34","author":"Tiegs","year":"2010","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ymthe.2022.09.012_bib6","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/hep.26754","article-title":"Macrophage plasticity and polarization in liver homeostasis and pathology","volume":"59","author":"Sica","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2022.09.012_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0118-x","article-title":"Accumulation of myeloid lineage cells is mapping out liver fibrosis post injury: a targetable lesion using Ketanserin","volume":"50","author":"Amini-Nik","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2022.09.012_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.ymthe.2022.09.012_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2022.09.012_bib10","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2022.09.012_bib11","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra1001683","article-title":"Current concepts hepatocellular carcinoma","volume":"365","author":"El-Serag","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.012_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2022.09.012_bib13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/gutjnl-2018-317257","article-title":"Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma","volume":"69","author":"Liu","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ymthe.2022.09.012_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.gt.3301647","article-title":"Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion","volume":"9","author":"Garcia-Banuelos","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2022.09.012_bib15","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acsnano.7b01522","article-title":"Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles","volume":"11","author":"Hu","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2022.09.012_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2008.07.006","article-title":"An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor","volume":"131","author":"Chono","year":"2008","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.ymthe.2022.09.012_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/0008-5472.CAN-16-0866","article-title":"Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors","volume":"77","author":"Miao","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2022.09.012_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bioactmat.2020.08.009","article-title":"Gold nanoparticles inhibit activation of cancer-associated fibroblasts by disrupting communication from tumor and microenvironmental cells","volume":"6","author":"Zhang","year":"2021","journal-title":"Bioactive Mater."},{"key":"10.1016\/j.ymthe.2022.09.012_bib19","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.1038\/s41467-020-19408-2","article-title":"Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer","volume":"11","author":"Desbois","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.012_bib20","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.6b02776","article-title":"The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors","volume":"10","author":"Miao","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2022.09.012_bib21","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.012_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2019.01.032","article-title":"Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy","volume":"448","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ymthe.2022.09.012_bib23","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1021\/acsnano.7b01786","article-title":"Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer","volume":"11","author":"Miao","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2022.09.012_bib24","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41467-019-10893-8","article-title":"Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy","volume":"10","author":"Hu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.012_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","article-title":"Collagen density regulates the activity of tumor-infiltrating T\u00a0cells","volume":"7","author":"Kuczek","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.09.012_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41392-020-00377-3","article-title":"Reprogramming immunosuppressive myeloid cells by activated T\u00a0cells promotes the response to anti-PD-1 therapy in colorectal cancer","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ymthe.2022.09.012_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.09.012_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052707","article-title":"PD-1\/PD-L1 Immuno-mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease","volume":"23","author":"Lombardi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2022.09.012_bib29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.09.012_bib30","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/clinchem\/hvab116","article-title":"Single cell and plasma RNA sequencing for RNA liquid biopsy for hepatocellular carcinoma","volume":"67","author":"Vong","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2022.09.012_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ymthe.2022.09.012_bib32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1164\/rccm.200504-613PP","article-title":"The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis","volume":"172","author":"Gelperina","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2022.09.012_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J.\u00a0Nanobiotechnol."},{"key":"10.1016\/j.ymthe.2022.09.012_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2022.09.012_bib35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.012_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.09.012_bib37","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.09.012_bib38","doi-asserted-by":"crossref","first-page":"19738","DOI":"10.18632\/oncotarget.7582","article-title":"PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis","volume":"7","author":"Passiglia","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2022.09.012_bib39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1158\/1078-0432.CCR-19-1040","article-title":"Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy","volume":"26","author":"Liu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2022.09.012_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-019-0547-7","article-title":"Correction to: persistent mutant oncogene specific T\u00a0cells in two patients benefitting from anti-PD-1","volume":"7","author":"Smith","year":"2019","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2022.09.012_bib41","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2022.09.012_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8(+) T\u00a0cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2022.09.012_bib43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.ymthe.2022.09.012_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.ymthe.2022.09.012_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7150\/ntno.30052","article-title":"Biological effects of nanoparticles on macrophage polarization in the tumor microenvironment","volume":"3","author":"Reichel","year":"2019","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.ymthe.2022.09.012_bib46","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/ja2084338","article-title":"Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake","volume":"134","author":"Walkey","year":"2012","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2022.09.012_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6596","article-title":"Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy","volume":"7","author":"Zhou","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2022.09.012_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2022.09.012_bib49","doi-asserted-by":"crossref","first-page":"e18534","DOI":"10.1371\/journal.pone.0018534","article-title":"Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1","volume":"6","author":"Boelte","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2022.09.012_bib50","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2022.09.012_bib51","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41467-018-04605-x","article-title":"Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap","volume":"9","author":"Song","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.09.012_bib52","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2022.09.012_bib53","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/bioinformatics\/btab003","article-title":"Nebulosa recovers single-cell gene expression signals by kernel density estimation","volume":"37","author":"Alquicira-Hernandez","year":"2021","journal-title":"Bioinformatics"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001622005664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:05:45Z","timestamp":1761501945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001622005664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1525001622005664"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022","name":"copyright","label":"Copyright"}]}}